Multiple agent diabetes therapy

Details Multiple agent diabetes therapy Multiple agent diabetes therapy

2008-01-29

2008-01-29

Lukton, David (Department: 1654)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

Glucagon; related peptides

C514S002600, C514S003100, C514S012200, C514S342000, C530S303000, C530S304000

Reexamination Certificate

active

11166390

ABSTRACT:
A pharmaceutical composition includes at least two of agents I)-iii), wherein agent i) is selected from the group consisting of an insulin, an insulin analog, a physiologically active fragment of said insulin and a physiologically active fragment of said insulin analog, agent ii) is selected from the group consisting of an insulin-related peptide, an insulin-related peptide analog, a physiologically active insulin-related peptide fragment and a physiologically active insulin-related peptide analog fragment, and agent iii) is an insulin sensitizer.

REFERENCES:
patent: 4652548 (1987-03-01), Chance et al.
patent: 4988675 (1991-01-01), Froesch et al.
patent: 5149777 (1992-09-01), Hansen et al.
patent: 5514646 (1996-05-01), Chance et al.
patent: 5527307 (1996-06-01), Srisathapat et al.
patent: 5569186 (1996-10-01), Lord et al.
patent: 5637095 (1997-06-01), Nason et al.
patent: 5641744 (1997-06-01), Cooper
patent: 5753681 (1998-05-01), Fujiwara et al.
patent: 5783556 (1998-07-01), Clark et al.
patent: 5958909 (1999-09-01), Habener
patent: 6136784 (2000-10-01), L'Italien et al.
patent: 6153632 (2000-11-01), Rieveley
patent: 6166042 (2000-12-01), Ikeda et al.
patent: 6166043 (2000-12-01), Ikeda et al.
patent: 6169099 (2001-01-01), Ikeda et al.
patent: 6169100 (2001-01-01), Ikeda et al.
patent: 6268343 (2001-07-01), Knudsen et al.
patent: 2003/0054979 (2003-03-01), Kim et al.
patent: 9220366 (1992-11-01), None
patent: 9602270 (1996-02-01), None
patent: 9857636 (1998-12-01), None
patent: 9943705 (1999-09-01), None
O. Molcuda et al., “Plasma Glucose Response After Intravenous Injection of Tolbutamide in Insulin- Treated Type I and Type II Diabetic Patients”,Exp. Clin. Endocrinol., vol. 91, No. 3, 1988, pp. 265-270.
J. Holst, “GLP-1 in NIDDM”,Diabetic Med., (9 Suppl. 6) Sep. 13, 1996, pp. S156-60.
A. Ryan et al., “Inslunotropic Hormone Glucagon-Like Peptide-1-(7-37) Appears not to Augment Insulin-Mediated Glucose Uptake in Young Men During Euglycemia”,J. of Clin. Endocrinology and Metabolism, vol. 83, No. 7, pp. 2399-2404.
B. Ahren et al., “Effects of Glucagon-Like Peptide-1 on Islet Function and Insulin Sensitivity in Noninsulin-Dependent Diabetes Mellius”, vol. 82, No. 2, pp. 473-478.
M. Toft-Nielsen et al., “The effect of Glucagon-Like Peptide I (GLP-I) on Glucose Elimination in Healthy Subjects Depends on the Pancreatic Glucoregulatory Hormones”,Diabetes, vol. 45, May 1996, pp. 552-556.
M. Cumiak, M.D., et al., “Antidiaborogenic Effect of Glucagon-Like Peptide-1 (7-36) Amide in Normal Subjects and Patients with Diabetes Mellitus”The New England Journal of Medicine, May 14, 1992, pp. 1316-1322.
U. Grau, “Life Support Systems, 1986,” Suppl. 1, Proc.—Eur. Soc. Artif. Organs, Annu. Mecr., 12th, 1985, 551-5.
H.M. Walter, Diabetes Research, 13(2):75-7, 1990.
Zhang, Science, 284:974-977, 1999.
Grau, Diabetes, 36(12):1453-1459, 1987.
J. Reif, Langmuis, 17(19):5801-5812, 2001.
H. Thurow, Diabetologia, 27(2):212-218, 1984.
G. Stangl, International Journal of Environmental Analytical Chemistry, 58(1-4):15-22, 1995.

Affiliated with

Also associated with

Rating

Multiple agent diabetes therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Multiple agent diabetes therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Multiple agent diabetes therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3942368